Hunter Syndrome
New Hunter syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), brain-directed enzyme delivery showed sustained CSF marker reductions in real-world follow-up, while care reports emphasized infusion logistics, long-term ERT planning, and supportive needs. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Brain-directed enzyme therapy. Evidence shifted from feasibility to longer interim real-world outcomes.
- Infusion setting and delivery. Reports added real-world comparisons and highlighted device-related burdens.
- Idursulfase beta in practice. Longer follow-up and switch experiences added routine-care context.
- Daily life and transitions. Patient-reported priorities and small supportive interventions gained visibility.
- After newborn screening. Second-tier markers and clearer follow-up steps reduced ambiguity focus.
New
September 2026
- Brain-targeted enzyme. A spinal-fluid marker dropped by week 24 and stayed lower.
- Procedure risks. Side effects were common, including some serious infections.
- Cognitive changes. Cognition changed differently in neuronopathic versus non-neuronopathic disease.
August 2026
- Hydrotherapy and pain. In a small adult study, hydrotherapy was linked to less pain impact.
- Quality of life. Quality-of-life scores improved during hydrotherapy in a very small study.
- After abnormal screen. A review outlined step-by-step testing after an abnormal newborn screen.
July 2026
- Enzyme therapy safety. Idursulfase beta reports did not show new safety concerns.
- Urine GAG levels. Urine GAG stayed lower with idursulfase beta treatment.
- Enzyme switch outcomes. After switching enzymes, 6-minute walk results stayed stable or improved.
June 2026
- Daily burdens. Families often named communication and movement limits as major burdens.
- Care transition support. A consistent care team and clear point person often helped.
- Screening lab accuracy. Lab quality checks were mostly accurate, with occasional mix-ups.
- Early lab finding. One lab chaperone approach did not lower stored material.
May 2026
- Starting enzyme therapy early. An expert consensus supported starting enzyme replacement therapy (ERT) early in both severe and milder forms of Hunter syndrome.
- ERT as long-term treatment. The same consensus described ERT as a long-term treatment for many people, including into adulthood, with stopping decisions made case by case.
- Earlier clues in routine care. In a small hospital review, one child was suspected earlier by a surgeon, which led to earlier diagnosis and earlier ERT.
- Stem cell transplant case report. One case report described a child with Hunter syndrome and Evans syndrome who improved after a stem cell transplant, but this is based on a single patient.
April 2026
- Follow-up after newborn screening. Extra blood and urine marker tests helped clarify newborn screening results that were not clear on the first test.
- Second marker reduced false positives. A second blood marker linked to GAG buildup helped distinguish confirmed Hunter syndrome cases from similar “look-alike” results.
- Eye symptoms in an adult case. One adult case report showed that eye problems can be a main presenting sign in an attenuated form of Hunter syndrome.
- New IDS variants reported. Newly reported IDS gene changes were described, supported by early computer modeling rather than direct functional testing.
March 2026
- First human dosing (not patients). One new therapy was tested in healthy adult volunteers, not yet in people with Hunter syndrome.
- Short-term tolerability. In this small study, short-term side effects were mostly mild and short-lived.
- Cell-based variant scoring. A lab imaging score separated different IDS gene variants based on how cells looked.
February 2026
- Spinal enzyme delivery and cognition. In very young boys with neuronopathic Hunter syndrome, thinking and learning scores were generally stable for several years after adding enzyme delivery into the spinal fluid, but certainty is limited because there was no comparison group.
- Implanted device complications. Some serious events were linked to the implanted delivery device (including infection) rather than the enzyme itself, which affects the long-term burden of this treatment approach.
- Hand and arm nerve damage over time. Over years of nerve testing, injury patterns in the arms and hands worsened, with larger changes in the median nerve and sensory signals than in the ulnar nerve or motor signals.
January 2026
- Infusion setting safety. Home idursulfase safety looked similar to clinic infusions.
- Missed infusion rates. Missed infusions were reported less often with home treatment.
- Meaningful test changes. Caregivers said small development test gains can still matter.
- Early animal findings. Animal studies increased IDS activity, but not shown in people.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Hunter syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).